Kyverna Therapeutics’ (KYTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kyverna Therapeutics (NASDAQ:KYTX) in a research report released on Wednesday morning,Benzinga reports. They currently have a $25.00 price objective on the stock.

A number of other equities analysts have also recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, JPMorgan Chase & Co. dropped their price target on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kyverna Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Kyverna Therapeutics Price Performance

Shares of Kyverna Therapeutics stock opened at $7.82 on Wednesday. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average price is $9.02 and its two-hundred day moving average price is $8.53. Kyverna Therapeutics has a 52 week low of $2.52 and a 52 week high of $13.67. The stock has a market cap of $475.38 million, a PE ratio of -2.38 and a beta of 1.95.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. As a group, sell-side analysts anticipate that Kyverna Therapeutics will post -2.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Phoenix Wealth Advisors grew its stake in Kyverna Therapeutics by 17.1% during the 4th quarter. Phoenix Wealth Advisors now owns 12,300 shares of the company’s stock valued at $116,000 after acquiring an additional 1,800 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in Kyverna Therapeutics during the 3rd quarter valued at about $28,000. Federated Hermes Inc. grew its stake in Kyverna Therapeutics by 36.6% during the 4th quarter. Federated Hermes Inc. now owns 20,705 shares of the company’s stock valued at $195,000 after acquiring an additional 5,547 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after acquiring an additional 5,694 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after acquiring an additional 6,400 shares in the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.